Model simulations and experimental validation confirm that simultaneous treatment with MEK-inhibitor and infection is most advantageous, suggesting that alternate (CAR-independent) regulatory mechanisms may be responsible for enhanced oncolysis. This evidence concerns the gene MAP2K7 and infection.